BenevolentAI SPAC Presentation Deck

The BenevolentAl business model - Leveraging our technology platform to generate new drug IP at scale Al-Discovery Tools 000 Target Identification Precision Medicine EO Knowledge Graph Molecular Design lo 100% owned in-house pipeline of novel discovery-stage assets taken to IND Platform Collaborations: Selective platform collaborations which can leverage the Platform in areas outside our core competencies A B Economic benefits BenevolentAl develop and commercialise Out-licence at IND, end Phase I or end Phase II (upfront, milestones, royalties) Platform validation Decision Criteria: • Feasibility of mid and late stage clinical development (size, specialism) • Fit with emerging commercialisation model • Funding environment Data generated enriches the BenevolentAl Platform Benevolent 32

View entire presentation